These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
67. Medipol: the guardian angel of biologics. Laue C; Ruppanner V Nanomedicine (Lond); 2006 Aug; 1(2):251-4. PubMed ID: 17716114 [TBL] [Abstract][Full Text] [Related]
68. Survey results on the use of the tissue cross-reactivity immunohistochemistry assay. Bussiere JL; Leach MW; Price KD; Mounho BJ; Lightfoot-Dunn R Regul Toxicol Pharmacol; 2011 Apr; 59(3):493-502. PubMed ID: 20951178 [TBL] [Abstract][Full Text] [Related]
69. Approach to assay validation for the development of biopharmaceuticals. Lundblad RL Biotechnol Appl Biochem; 2001 Dec; 34(3):195-7. PubMed ID: 11785468 [No Abstract] [Full Text] [Related]
70. Stability studies needed to define the handling and transport conditions of sensitive pharmaceutical or biotechnological products. Ammann C AAPS PharmSciTech; 2011 Dec; 12(4):1264-75. PubMed ID: 21948319 [TBL] [Abstract][Full Text] [Related]
71. Meeting report-workshop on spike characterizations and virus removal by filtration: trends and new developments. Willkommen H; Blümel J; Brorson K; Chen D; Chen Q; Gröner A; Hubbard BR; Kreil TR; Ruffing M; Ruiz S; Scott D; Silvester G PDA J Pharm Sci Technol; 2014; 68(3):215-20. PubMed ID: 25188344 [TBL] [Abstract][Full Text] [Related]
72. Predictive DMPK: in silico ADME predictions in drug discovery. Kenny JR Mol Pharm; 2013 Apr; 10(4):1151-2. PubMed ID: 23540938 [No Abstract] [Full Text] [Related]
73. Cellular targets for improved manufacturing of virus-based biopharmaceuticals in animal cells. Rodrigues AF; Carrondo MJ; Alves PM; Coroadinha AS Trends Biotechnol; 2014 Dec; 32(12):602-7. PubMed ID: 25450042 [TBL] [Abstract][Full Text] [Related]
74. Strategies for Maximizing Successful Drug Substance Technology Transfer Using Engineering, Shake-Down, and Wet Test Runs. Abraham S; Bain D; Bowers J; Larivee V; Leira F; Xie J PDA J Pharm Sci Technol; 2015; 69(5):650-7. PubMed ID: 26429113 [TBL] [Abstract][Full Text] [Related]
75. Hybrid modeling for quality by design and PAT-benefits and challenges of applications in biopharmaceutical industry. von Stosch M; Davy S; Francois K; Galvanauskas V; Hamelink JM; Luebbert A; Mayer M; Oliveira R; O'Kennedy R; Rice P; Glassey J Biotechnol J; 2014 Jun; 9(6):719-26. PubMed ID: 24806479 [TBL] [Abstract][Full Text] [Related]
76. Antibodies and other biopharmaceuticals. Jungbauer A Biotechnol J; 2008 Oct; 3(9-10):1103. PubMed ID: 18932164 [No Abstract] [Full Text] [Related]
77. Trends in ion channel drug discovery: advances in screening technologies. Bennett PB; Guthrie HR Trends Biotechnol; 2003 Dec; 21(12):563-9. PubMed ID: 14624866 [No Abstract] [Full Text] [Related]
79. Continuous downstream processing of biopharmaceuticals. Jungbauer A Trends Biotechnol; 2013 Aug; 31(8):479-92. PubMed ID: 23849674 [TBL] [Abstract][Full Text] [Related]
80. Recent Topics of Research in the Characterization and Quality Control of Biopharmaceuticals in Japan. Ishii-Watabe A; Shibata H; Harazono A; Hyuga M; Kiyoshi M; Saitoh S; Iwura T; Torisu T; Goda Y; Uchiyama S J Pharm Sci; 2017 Dec; 106(12):3431-3437. PubMed ID: 28802881 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]